<DOC>
	<DOCNO>NCT00002553</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Bone marrow transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill tumor cell . PURPOSE : Phase II trial study effectiveness bone marrow transplantation use unrelated bone marrow donor treat patient hematologic cancer .</brief_summary>
	<brief_title>Chemotherapy Plus Radiation Therapy Biological Therapy Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether use donor one non crossreactive group ( CREG ) mismatch HLA-A B patient less 36 year age associate frequent graft versus host disease ( GVHD ) grade III-IV previously observe donor one CREG mismatch . II . Determine whether use donor one CREG mismatch HLA-A B patient 36-50 year age associate frequent GVHD grade III-IV previously observe matched donor . III . Determine relevance HLA-A allele mismatch bone marrow transplant donor match HLA-A , B , DR phenotypes . OUTLINE : This parallel , open label study . Patients assign 1 3 treatment arm . Arm I : Patients receive cyclophosphamide IV day -7 -6 total body irradiation ( TBI ) 3 time day day -4 -1 . Allogeneic bone marrow ( ABM ) infuse day 0 . Arm II : Patients receive therapy arm I , except TBI administer twice day day -1 . ABM infuse day 0 . Arm III : Patients receive cyclophosphamide IV day -6 -5 TBI twice day day -3 -1 . ABM infuse day 0 . Males ALL receive additional radiation boost testis TBI . Patients follow least every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 50 patient 36 year old 50 patient 36-50 year old accrue study within 5 year . Additional patient accrue standard therapy arm study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Hematologic malignancy follow type : Chronic myelogenous leukemia ( CML ) chronic accelerate phase Newly diagnose acute leukemia high risk relapse follow chemotherapy alone Early referral encourage donor search begin soon possible Acute leukemia fail one cycle induction chemotherapy Acute leukemia beyond first remission Highrisk Hodgkin 's disease nonHodgkin 's lymphoma first remission Hodgkin 's disease , nonHodgkin 's lymphoma , malignant lymphoproliferative disease first remission No suitable relate donor available ( i.e. , HLA genotypically identical sibling ) No haploidentical relative 1 unshared haplotype HLAA , B , D locus Acute leukemia relapse CML blast crisis eligible following condition : Patient 's clinical condition likely remain stable 26 month period necessary find marrow donor Remission induction attempt Local physician patient accept search transplant may cancel patient 's condition deteriorate search No leukoencephalopathy Donor requirement : Age less 60 In good health Phenotypically identical HLAA , B , DRB1 1antigen mismatch HLAA , B , DRB1 locus allow patient age 36 Patients TBI contraindicate may treat protocol FHCRC739 Severe aplastic anemia transplant accord protocol FHCRC174.2 FHCRC800 Myelodysplastic syndrome transplant accord protocol FHCRC179.3 FHCRC844 PATIENT CHARACTERISTICS : Age : Under 56 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : No acute hepatitis No severe hepatic disease Renal : Creatinine le 2 time normal age , weight , sex Cardiovascular : No symptomatic cardiac disease Pulmonary : No active pulmonary disease No history pulmonary fibrosis No severe hypoxemia ( pO2 less 70 mm Hg DLCO le 70 % ) No mild hypoxemia ( pO2 less 80 mm Hg DLCO le 60 % ) Other : HIV negative No severe limitation due disease malignancy PRIOR CONCURRENT THERAPY : No 3,000 cGy whole brain No 1,500 cGy chest abdomen At least 6 month since involvedfield irradiation chest abdomen</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent adult non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>